



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 2/21/2019  
LAST REVIEW DATE: 2/17/2022  
LAST CRITERIA REVISION DATE: 2/17/2022  
ARCHIVE DATE:

---

## DAURISMO™ (glasdegib) oral tablet

---

Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as "**Description**" defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as "**Criteria**" defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

**BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.**

---

This Pharmacy Coverage Guideline does not apply to FEP or other states' Blues Plans.

Information about medications that require precertification is available at [www.azblue.com/pharmacy](http://www.azblue.com/pharmacy).

Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements.

All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums.

Precertification for medication(s) or product(s) indicated in this guideline requires completion of the [request form](#) in its entirety with the chart notes as documentation. **All requested data must be provided.** Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) 864-3126 or emailed to [Pharmacyprecert@azblue.com](mailto:Pharmacyprecert@azblue.com). **Incomplete forms or forms without the chart notes will be returned.**



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 2/21/2019  
LAST REVIEW DATE: 2/17/2022  
LAST CRITERIA REVISION DATE: 2/17/2022  
ARCHIVE DATE:

---

## DAURISMO™ (glasdegib) oral tablet

---

### Criteria:

- **Criteria for initial therapy:** Daurismo (glasdegib) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Prescriber is a physician specializing in the patient's diagnosis or is in consultation with an Oncologist
  2. A confirmed diagnosis of **ONE** of the following:
    - a. Used in combination with low-dose cytarabine for treatment of newly-diagnosed Acute Myeloid Leukemia (AML) in patients who are at least 75 years of age, or who have significant comorbid conditions that preclude use of intensive induction chemotherapy (i.e., severe cardiac disease, Eastern Co-operative Oncology Group (ECGO) performance status 0-2, or baseline creatinine > 1.3 mg/dL)
    - b. Other request for a specific oncologic direct treatment use that is found and listed in the National Comprehensive Cancer Network (NCCN) Guidelines with Categories of Evidence and Consensus of 1 and 2A
  3. Individual does not have end stage renal disease requiring hemodialysis
  4. **ALL** of the following baseline tests have been completed before initiation of treatment with continued monitoring as clinically appropriate:
    - a. Negative pregnancy test in a woman of childbearing potential
    - b. Serum creatine kinase
    - c. Electrocardiogram
    - d. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
  5. There are no significant interacting drugs

**Initial approval duration:** 6 months

- **Criteria for continuation of coverage (renewal request):** Daurismo (glasdegib) is considered *medically necessary* and will be approved when **ALL** of the following criteria are met:
1. Individual continues to be seen by a physician specializing in the patient's diagnosis or is in consultation with an Oncologist
  2. Individual's condition has responded while on therapy
    - a. Response is defined as:
      - i. Documented evidence of efficacy, disease stability and/or improvement
      - ii. No evidence individual has developed any significant unacceptable adverse drug reactions that may exclude continued use
  3. Individual has been adherent with the medication



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 2/21/2019  
LAST REVIEW DATE: 2/17/2022  
LAST CRITERIA REVISION DATE: 2/17/2022  
ARCHIVE DATE:

---

## DAURISMO™ (glasdegib) oral tablet

---

- 4. Individual does not have end stage renal disease requiring hemodialysis
- 5. Individual has not developed any significant adverse drug effects that may exclude continued use
  - a. Significant adverse effect such as:
    - i. Life threatening QTc interval prolongation with life-threatening arrhythmia
    - ii. Platelets < 10,000 cells/mm<sup>3</sup> for more than 42 days in the absence of disease
    - iii. Neutrophil count < 500 cells/mm<sup>3</sup> for more than 42 days in the absence of disease
    - iv. Severe nonhematologic toxicity that recues after dose modification
    - v. Any first occurrence of life-threatening non-hematologic toxicity
- 6. There are no significant interacting drugs

**Renewal duration:** 12 months

- Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:
  - 1. **Off-Label Use of Non-cancer Medications**
  - 2. **Off-Label Use of Cancer Medications**

---

### **Description:**

Daurismo (glasdegib) is a hedgehog pathway inhibitor indicated, in combination with low dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. Daurismo (glasdegib) has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.

AML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of abnormal white blood cells in the bloodstream and bone marrow. Approximately half of the adults diagnosed with AML are not treated with intensive chemotherapy because of comorbidities and chemotherapy related toxicities.

---

### **Definitions:**

#### **Eastern Co-operative Oncology Group (ECGO) Performance Status:**

Grade	ECOG description
0	Fully active, able to carry on all pre-disease performance without restriction
1	Restricted in physical strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
2	Ambulatory and capable of all self-care but unable to carry out any work activities, up and about more than 50% of waking hours



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINES  
SECTION: DRUGS

ORIGINAL EFFECTIVE DATE: 2/21/2019  
LAST REVIEW DATE: 2/17/2022  
LAST CRITERIA REVISION DATE: 2/17/2022  
ARCHIVE DATE:

---

## DAURISMO™ (glasdegib) oral tablet

---

3	Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4	Completely disabled, cannot carry on any self-care, totally confined to bed or chair
5	Dead
Oken, MM, Creech, RH, Tormey, DC, et al.: Toxicity and Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982	

---

### Resources:

Daurismo (glasdegib) product information, revised by Pfizer Laboratories Div Pfizer Inc. 03-2020. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed December 07, 2021.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Acute Myeloid Leukemia Version 1.2022 – Updated December 02, 2021. Available at <https://www.nccn.org>. Accessed December 07, 2021.

Off Label Use of Cancer Medications: A.R.S. §§ 20-826(R) & (S). Subscription contracts; definitions.

Off Label Use of Cancer Medications: A.R.S. §§ 20-1057(V) & (W). Evidence of coverage by health care service organizations; renewability; definitions.